News | August 14, 2019

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 14, 2019– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...

News | August 13, 2019

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors – Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – – Median Progression Free...

News | July 29, 2019

ARVINAS APPOINTS RONALD PECK, M.D. AS CHIEF MEDICAL OFFICER NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the...

News | August 1, 2019

Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy Reimbursement for Company’s non-drug depression treatment, NeuroStar® Advanced Therapy, enables access for depression sufferers in Japan MALVERN, Pa., Aug. 1, 2019 /PRNewswire/...

News | July 29, 2019

Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients Enhanced software efficiencies include user-friendly mobile interface and data export to electronic medical records capability MALVERN, Pa., July 29, 2019...

News | June 26, 2019

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a...